Mazurier Christelle, Douay Luc
INSERM, UMRS938, Prolifération et différenciation des cellules souches, 75012 Paris, France - Etablissement Français du Sang Ile de France, Unité d'ingénierie et de thérapie cellulaire, 94017 Créteil, France - UPMC Université ParisVI, UMRS938 CDR Saint-Antoine, Prolifération et différenciation des cellules souches, 75012 Paris, France.
INSERM, UMRS938, Prolifération et différenciation des cellules souches, 75012 Paris, France - Etablissement Français du Sang Ile de France, Unité d'ingénierie et de thérapie cellulaire, 94017 Créteil, France - UPMC Université ParisVI, UMRS938 CDR Saint-Antoine, Prolifération et différenciation des cellules souches, 75012 Paris, France - AP-HP, Hôpital Armand Trousseau et Saint-Antoine, Service d'Hématologie et Immunologie Biologiques, 75012 Paris, France.
Biol Aujourdhui. 2016;210(1):9-17. doi: 10.1051/jbio/2016008. Epub 2016 Jun 10.
Human adult pluripotent stem cells, stem cells of embryonic origin and induced pluripotent stem cells (iPS) provide cellular sources for new promising regenerative medicine approaches. Because these cells can be patient-specific, they allow considering a personalized medicine appropriate to the diagnosis of each. The generation of cultured red blood cells (cRBC) derived from stem cells is emblematic of personalized medicine. Indeed, these cells have the advantage of being selected according to a blood phenotype of interest and they may provide treatments to patients in situation of impossible transfusion (alloimmunized patients, rare phenotypes). Essential progresses have established proof of concept for this approach, still a concept some years ago. From adult stem cells, all steps of upstream research were successfully achieved, including the demonstration of the feasibility of injection into human. This leads us to believe that Red Blood Cells generated in vitro from stem cells will be the future players of blood transfusion. However, although theoretically ideal, these stem cells raise many biological challenges to overcome, although some tracks are identified.
人类成体多能干细胞、胚胎来源的干细胞和诱导多能干细胞（iPS）为新的、有前景的再生医学方法提供了细胞来源。由于这些细胞可以是患者特异性的，因此可以考虑针对每个患者的诊断采用个性化医疗。源自干细胞的培养红细胞（cRBC）的产生是个性化医疗的一个典型例子。事实上，这些细胞具有根据感兴趣的血型进行选择的优势，并且可以为无法进行输血的患者（同种免疫患者、罕见血型患者）提供治疗。尽管几年前这还只是一个概念，但该方法的概念验证已经取得了实质性进展。从成体干细胞开始，上游研究的所有步骤都已成功完成，包括证明了将其注入人体的可行性。这使我们相信，由干细胞体外生成的红细胞将成为未来输血的主力军。然而，尽管从理论上讲这些干细胞很理想，但它们也带来了许多生物学挑战有待克服，尽管已经确定了一些研究方向。
